Brookings AI Healthcare Case Study: $200-$360B Savings, Mayo Clinic & the Policy Roadmap

The Scale of the AI Healthcare Opportunity: 17.6% of US GDP

The Brookings Institution’s AI healthcare case study arrives at a critical moment for the world’s most expensive healthcare system. US healthcare spending represents 17.6% of GDP — a staggering figure that reflects both the sector’s importance and its inefficiencies. Against this backdrop, AI represents perhaps the most significant opportunity to simultaneously improve outcomes and reduce costs.

The headline economic estimate is striking: AI could raise US healthcare productivity by 5–10% over five years, worth approximately $200–$360 billion in 2019 dollars (Sahni et al. 2024). This potential savings spans clinical decision support, administrative automation, drug discovery acceleration, and operational efficiency gains. But the Brookings analysis is characteristically balanced — it pairs this optimistic projection with a rigorous examination of barriers, risks, and the policy framework needed to realize AI’s healthcare potential safely.

The human cost context is equally compelling. Medical errors contribute to approximately 10% of US patient deaths according to the Agency for Healthcare Research and Quality, while an estimated 795,000 US patients per year suffer serious harm from diagnostic errors (BMJ Quality & Safety). AI-powered diagnostic tools have the potential to dramatically reduce these numbers through improved accuracy, consistency, and early detection. For healthcare leaders tracking AI transformation in healthcare, this Brookings case study provides the most comprehensive policy-oriented framework available.

Clinical Decision Support: AI as Diagnostic Partner, Not Replacement

The Brookings AI healthcare case study makes a crucial distinction: AI should initially function as a clinician decision-support tool (human-in-the-loop), not as an autonomous diagnostician. This positioning acknowledges both AI’s capabilities and its current limitations, while managing the regulatory and liability complexities of clinical deployment.

AI excels in several clinical decision support roles: pattern recognition in medical imaging (identifying subtle abnormalities in X-rays, CT scans, and pathology slides), risk stratification (flagging patients at elevated risk based on electronic health record analysis), diagnostic consistency (reducing the variability that occurs between human clinicians, particularly in image interpretation), and early warning (detecting deterioration patterns before they become clinically obvious).

The key insight from the Brookings analysis is that AI’s diagnostic value is maximized when it augments rather than replaces clinical judgment. The technology handles pattern recognition at scale and speed that humans cannot match, while clinicians provide the contextual understanding, patient communication, and ethical judgment that AI cannot replicate. This complementary model aligns with the broader AI deployment pattern across industries: AI handles analysis, humans handle judgment.

Mayo Clinic: The AI Healthcare Case Study in Real-World Practice

The Mayo Clinic emerges as a central case study in the Brookings report, demonstrating what practical AI deployment looks like in a world-class healthcare system. Several implementations illustrate the range of AI applications:

Polycystic Kidney Disease Assessment

AI automated the kidney-volume assessment process that previously required approximately 45 minutes per patient, producing comparable results in seconds. This represents a paradigm shift in clinical efficiency — freeing specialist time for complex decision-making while maintaining diagnostic quality.

Medical Scan Analysis and Risk Assessment

Mayo Clinic deploys AI across multiple imaging modalities to assist radiologists and specialists in identifying abnormalities, quantifying disease progression, and stratifying patient risk. These systems operate as second readers, providing an additional check that can catch findings a human reader might miss during high-volume workdays.

Clinical Notes and Administrative Reduction

AI-powered clinical documentation tools assist physicians in generating patient notes from conversations, reducing the administrative burden that contributes significantly to physician burnout. Given that approximately 40% of doctors report considering leaving their organizations (AMA survey/Berg 2023), this application addresses a critical workforce sustainability issue.

AI in Drug Discovery: AlphaFold, Xaira, and Billion-Dollar Bets

Drug discovery represents the highest-stakes application in the Brookings AI healthcare case study. With average pharmaceutical R&D costs reaching approximately $2 billion per new drug (US, 2016–2020), and pharmaceutical manufacturing productivity actually declining over recent decades, the industry desperately needs transformative efficiency gains.

AlphaFold2 from Google DeepMind stands as the landmark achievement — AI models that predict protein structures with unprecedented accuracy, opening entirely new pathways for drug target identification. The Brookings report notes that AlphaFold has fundamentally accelerated the early stages of drug discovery by making protein structure prediction accessible to researchers worldwide.

The venture capital response validates the opportunity. Xaira Therapeutics launched in 2024 with approximately $1 billion in backing to advance AI-driven drug discovery from academic labs to clinical application. Inceptive raised $100 million to design vaccines and therapies with AI. However, the Brookings analysis adds important caveats: the AI drug discovery space also shows volatility, with firms like BenevolentAI experiencing layoffs in 2024 — a reminder that transformative technology doesn’t guarantee commercial success.

Pharmaceutical manufacturing productivity data tells a sobering story. Output per hour showed positive trends through the 1990s (+1.12% annualized, 1987–1995) but has been negative since 2007 (−3.41% annualized, 2007–2018). AI’s promise in this context isn’t just about incremental improvement — it’s about reversing a decades-long productivity decline in one of the world’s most important industries.

Administrative Automation: Reducing Healthcare’s Paperwork Burden

The Brookings AI healthcare case study identifies administrative automation as perhaps the lowest-risk, highest-return application of AI in healthcare. Administrative tasks — data entry, clinical documentation, scheduling, billing, coding, prior authorization — consume enormous amounts of clinician time and contribute significantly to burnout.

The scale of administrative burden in US healthcare is staggering. Physicians report spending nearly as much time on documentation as on patient care, creating a perverse dynamic where the healthcare system’s most expensive and highly trained workers perform tasks that AI could handle more efficiently. The ~40% of physicians considering leaving practice cite administrative burden as a primary factor — making AI-powered automation not just an efficiency play but a workforce retention strategy.

Current AI applications in healthcare administration include: ambient clinical documentation (AI that generates clinical notes from doctor-patient conversations), intelligent scheduling (optimizing appointment slots based on patient complexity, provider expertise, and resource availability), automated coding and billing (translating clinical encounters into accurate billing codes), and prior authorization assistance (accelerating insurance approval processes that currently delay patient care).

The Trust Problem: When AI + Clinicians Paradoxically Underperform

One of the most important findings in the Brookings AI healthcare case study challenges the intuitive assumption that AI + humans always beats either alone. Research by Agarwal et al. (2023) found that combining AI with clinicians sometimes degrades outcomes because clinicians either over-defer to AI recommendations (accepting errors they would have caught independently) or under-utilize AI insights (ignoring correct AI suggestions that contradict their clinical intuition).

This finding has profound implications for how AI is deployed in clinical settings. Simply providing AI recommendations alongside clinician judgment isn’t sufficient — the interaction design between AI systems and clinicians matters enormously. Effective AI-clinician collaboration requires clear protocols for when to follow AI recommendations, when to override them, and how to calibrate trust appropriately.

The Brookings analysis recommends addressing this through systematic training programs that teach clinicians about AI capabilities and limitations, interface design that presents AI recommendations with appropriate confidence levels and reasoning, and continuous monitoring that tracks whether AI-clinician combinations actually improve outcomes in specific clinical contexts. This nuanced view distinguishes the Brookings approach from simpler narratives about AI’s transformative healthcare potential, connecting to broader deep learning deployment challenges.

Five Barriers to Healthcare AI Adoption

The Brookings AI healthcare case study identifies five structural barriers that must be addressed for AI to achieve its healthcare potential:

1. AI Hallucinations and Incorrect Outputs

Generative AI models can produce confident-sounding but factually incorrect medical information, including fabricated references (Wu et al. 2024; Greenstein et al. 2024). In healthcare, where errors can cause patient harm, this tendency toward hallucination represents a fundamental safety concern that requires robust verification mechanisms.

2. Fragmented Data and Interoperability Gaps

Healthcare data remains siloed across institutions, with inconsistent coding practices, incompatible EHR systems, and varying imaging protocols. Training clinically useful AI models requires access to large, diverse, standardized datasets — which the current healthcare data infrastructure does not readily provide.

3. Clinician Trust and Adoption Resistance

Healthcare professionals express legitimate skepticism about AI quality and reliability. Nurses and physicians worry about over-reliance on systems they don’t fully understand, while organizational leaders and frontline staff often disagree on the pace and scope of AI deployment.

4. Regulatory Uncertainty and Liability Questions

Who is liable when an AI system makes a diagnostic error? The developer, the hospital, or the clinician who accepted the AI recommendation? Evolving regulatory frameworks (Stern 2022) haven’t yet provided clear answers, creating legal uncertainty that slows adoption.

5. Economic Volatility in AI Health Companies

Large investments followed by sudden cutbacks (as seen with some AI drug discovery firms in 2024) reflect the early-stage, high-risk nature of healthcare AI commercialization. Sustainable deployment requires business models that generate measurable clinical value, not just venture capital excitement.

Brookings Policy Recommendations for Healthcare AI Adoption

The Brookings AI healthcare case study concludes with a comprehensive policy framework spanning six areas:

Regulatory Standards & Validation: Create clear, proportionate FDA/regulatory pathways for AI medical devices and LLM-based tools. Require clinical trials and real-world validation for high-risk AI medical applications. Establish reproducibility and safety benchmarks.

Data Infrastructure & Interoperability: Invest in secure, standardized EHR data-sharing frameworks (FHIR adoption, common ontologies). Strengthen data custodianship and consent models to enable responsible model training while protecting patient privacy.

Liability & Reimbursement: Clarify liability rules for AI-assisted care with human-in-the-loop standards. Update reimbursement models to reward validated AI-enabled efficiency and improved outcomes — creating financial incentives for adoption.

Trust-Building & Workforce Preparedness: Fund pilot programs with rigorous evaluation and clinician co-design. Train clinicians on AI limitations, interpretation, and appropriate reliance through continuous education programs.

R&D Support & Translation: Provide public/private funding for pre-competitive datasets, benchmark tasks, and translational projects that move promising AI from laboratories to clinical practice. Encourage open-science resources to accelerate reproducibility.

Safety-First Deployment: Require explainability and chain-of-thought reasoning where feasible for clinical decision-making. Mandate human oversight for high-risk decisions, consistent with the emerging technology governance frameworks across industries.

What the Brookings AI Healthcare Case Study Means for Leaders and Investors

Three strategic implications emerge from the Brookings analysis:

The Productivity Prize Is Real but Conditional

$200–$360 billion in potential healthcare savings is not a forecast — it’s a conditional estimate that depends on regulatory clarity, data infrastructure, workforce adaptation, and sustained investment. Organizations should plan for AI’s healthcare impact but avoid assuming the full savings will materialize without addressing the structural barriers.

Administrative AI Offers the Fastest Path to Value

While clinical diagnostic AI captures headlines, administrative automation offers lower risk, clearer regulatory pathways, and more immediate ROI. Healthcare organizations should prioritize documentation, scheduling, and billing AI while building the evidence base and regulatory frameworks needed for clinical applications.

The Human-AI Interaction Design Is Everything

The finding that AI + clinicians can underperform either alone underscores that technology deployment without interaction design is insufficient. Healthcare organizations must invest in workflow integration, training protocols, and continuous outcome monitoring — not just AI technology procurement. The institutions that master the human-AI collaboration model will capture disproportionate value.